{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:34:17Z","timestamp":1793255657676,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Warner Chilcott"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>It is essential to closely monitor the response to oral bisphosphonate therapy for osteoporosis, as many patients are nonadherent. The conventional approach is to monitor whether changes in BMD or bone turnover markers (BTMs) exceed the least significant change. This approach assumed that if a patient were not receiving a treatment, there would be no change in the BMD. We propose an alternative approach, that of expected change. We define this expected change as the change in BMD (at 24\u00a0mo) or BTMs (at 3\u00a0mo) that is exceeded in 90% of patients who are adherent with oral bisphosphonate therapy. We studied 108 postmenopausal women (age\u2009&amp;lt;\u200985\u00a0yr) who were randomized to the licensed dose of alendronate, ibandronate, or risedronate treatment for 2\u00a0yr, along with calcium and vitamin D supplementation. We identified the performance of BMD and BTMs in 3 ways. We calculated the signal-to-noise ratio, which was lower for BMD (4.1 and 2.1 for lumbar spine BMD (LSBMD) and total hip BMD (THBMD), respectively) compared to BTMs (9.4 and 10.2 for C-telopeptide of type I collagen (CTX) and procollagen I N-propeptide (PINP), respectively). We estimated the response rate as the percentage of women exceeding the least significant change, which was lower for BMD (47% and 24% for LSBMD and THBMD, respectively) than for BTMs (96% and 94% for CTX and PINP, respectively). We estimated the expected change as the 90th (or 10th) percentile of change in adherent patients. We required the expected change to exceed the least significant change, and this was not observed for LSBMD and THBMD, but it was observed for CTX and PINP (expected changes of 0.233 and 12.1\u00a0ng\/mL, respectively). Thus, the BTMs CTX and PINP showed the best performance as response markers for monitoring oral bisphosphonate treatment, and the new approach is based on a biological rather than a statistical endpoint when using the expected change approach.<\/jats:p>","DOI":"10.1093\/jbmr\/zjag039","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T12:32:24Z","timestamp":1771763544000},"page":"1202-1208","source":"Crossref","is-referenced-by-count":1,"title":["Expected change: a new concept for monitoring patients on oral bisphosphonates"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2204-2095","authenticated-orcid":false,"given":"Marian","family":"Schini","sequence":"first","affiliation":[{"name":"Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield , Sheffield S10 2RX ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1030-0723","authenticated-orcid":false,"given":"Margaret A","family":"Paggiosi","sequence":"additional","affiliation":[{"name":"Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield , Sheffield S10 2RX ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1433-2001","authenticated-orcid":false,"given":"Fatma","family":"Gossiel","sequence":"additional","affiliation":[{"name":"Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield , Sheffield S10 2RX ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R","family":"Cummings","sequence":"additional","affiliation":[{"name":"San Francisco Coordinating Center , CA 94158 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-3366","authenticated-orcid":false,"given":"Richard","family":"Eastell","sequence":"additional","affiliation":[{"name":"Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield , Sheffield S10 2RX ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"3","key":"2026102901480309500_ref1","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00198-017-3906-6","article-title":"International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates","volume":"28","author":"Diez-Perez","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026102901480309500_ref2","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/jbmr.2023","article-title":"Risk factors for treatment failure with antiosteoporosis medication: the global longitudinal study of osteoporosis in women (GLOW)","volume":"29","author":"D\u00edez-P\u00e9rez","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2026102901480309500_ref3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/endrev\/bnac031.2023","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini","year":"2023","journal-title":"Endocr Rev"},{"issue":"18","key":"2026102901480309500_ref4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2026102901480309500_ref5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/ng.2492","article-title":"Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3","volume":"45","author":"Nesbit","year":"2013","journal-title":"Nat Genet"},{"issue":"12","key":"2026102901480309500_ref6","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s00198-014-2817-z","article-title":"Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study","volume":"25","author":"Paggiosi","year":"2014","journal-title":"Osteoporos Int"},{"issue":"11","key":"2026102901480309500_ref7","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00198-013-2386-6","article-title":"Adherence to raloxifene therapy: assessment methods and relationship with efficacy","volume":"24","author":"Finigan","year":"2013","journal-title":"Osteoporos Int"},{"issue":"12","key":"2026102901480309500_ref8","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1359\/jbmr.1998.13.12.1797","article-title":"Changes in bone turnover induced by aerobic and anaerobic exercise in young males","volume":"13","author":"Woitge","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026102901480309500_ref9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos Int"},{"issue":"Jul","key":"2026102901480309500_ref10","doi-asserted-by":"crossref","first-page":"115336","DOI":"10.1016\/j.bone.2020.115336","article-title":"The challenge of long-term adherence: the role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis","volume":"136","author":"Fontalis","year":"2020","journal-title":"Bone"},{"issue":"4","key":"2026102901480309500_ref11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1385\/JCD:8:4:371","article-title":"Precision assessment and radiation safety for dual-energy X-ray absorptiometry: position paper of the International Society for Clinical Densitometry","volume":"8","author":"Baim","year":"2005","journal-title":"J Clin Densitom"},{"key":"2026102901480309500_ref12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/9781118453926.ch119","volume-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","author":"Shapses","year":"2013"},{"issue":"4","key":"2026102901480309500_ref13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1359\/jbmr.1999.14.4.602","article-title":"Monitoring alendronate therapy for osteoporosis","volume":"14","author":"De Castro Machado","year":"1999","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2026102901480309500_ref14","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/jbmr.342","article-title":"Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence","volume":"26","author":"Eastell","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"Suppl 3","key":"2026102901480309500_ref15","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1007\/BF01623003","article-title":"Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women","volume":"3","author":"Chesnut","year":"1993","journal-title":"Osteoporos Int"},{"issue":"4","key":"2026102901480309500_ref16","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/jbmr3355","article-title":"Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression","volume":"33","author":"Bauer","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026102901480309500_ref17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1185\/030079905X75096","article-title":"Development of an algorithm for using PINP to monitor treatment of patients with teriparatide","volume":"22","author":"Eastell","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2026102901480309500_ref18","doi-asserted-by":"publisher","first-page":"R19","DOI":"10.1530\/EJE-17-0585","article-title":"Diagnosis of endocrine disease: bone turnover markers: are they clinically useful?","volume":"178","author":"Eastell","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026102901480309500_ref19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S2213-8587(20)30159-5","article-title":"Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials","volume":"8","author":"Black","year":"2020","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmr\/advance-article-pdf\/doi\/10.1093\/jbmr\/zjag039\/67067972\/zjag039.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/11\/1202\/67067972\/zjag039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/41\/11\/1202\/67067972\/zjag039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:48:11Z","timestamp":1793252891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/41\/11\/1202\/8494655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":19,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,10,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmr\/zjag039","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,2,23]]}}}